Novo Nordisk (CPSE:NOVO B) is rolling out its oral Ozempic (semaglutide) tablet across the US as the only FDA approved oral GLP-1 for adults with type 2 diabetes. The company plans broad distribution ...

Novo Nordisk will launch its oral Ozempic pill for type 2 diabetes in the U.S. next week, offering competitive pricing and broad pharmacy availability. The move comes as rival Eli Lilly gains momentum ...

Novo Nordisk (NYSE:NVO) has drawn investor attention after recent share price moves, with the stock showing a monthly gain alongside weaker past 3 months and 1 year total returns, prompting closer ...

Novo Nordisk A/S upgraded to Hold as FDA tightens compounded GLP-1s;Hims & Hers Health, Inc. stays Buy. Click for this NVO ...

Health Canada approved on Tuesday the first generic version of Danish drugmaker Novo Nordisk's Ozempic drug.

Novo Nordisk (NVO) stock is in focus as the company launches oral semaglutide as Ozempic pill for patients with type 2 ...

Novo Nordisk CEO Mike Doustdar sits down with CNN to discusses manufacturing Wegovy pill in the U.S, direct to consumer ...

CNBC’s Fast Money panel recently made a notable pivot on its April 24 episode, arguing that Novo Nordisk (NYSE:NVO | NVO ...

The pharmaceutical industry has rarely seen a stock rise as spectacularly as Novo Nordisk (NVO 0.69%) did during the GLP-1 ...

The drugmaker is getting on the AI train in ways that could move the needle down the road.

Novo Nordisk A/S is rebranding an existing, less-popular diabetes tablet as Ozempic in the US in a bid to capitalize on the ...

The Food and Drug Administration proposed excluding Novo Nordisk and Eli Lilly's weight-loss drugs from a key compounding ...